13 Jun 2022

Benefits of Nasal Drug Delivery – More than just Hay Fever

In this webinar, speaker Gemma Budd, Director of Business Development, Nanopharm, will highlight the considerations for both systemic/N2B and intranasal vaccines, and the differences in approach when designing the best device and formulation combination. This session was originally broadcast as part of the Pharmapack Europe 2022. Nasal sprays have been around for decades to successfully manage conditions such as allergic rhinitis (hayfever), where treatment of the nasal cavity is the target. Locally acting nasal drug products continue to be developed to treat other infectious diseases, with a big focus on biologic molecules. Furthermore, the COVID-19 pandemic has accelerated the interest in intranasal vaccine administration to enable rapid roll out of vaccines with fewer supply chain challenges for respiratory diseases, and these products target the NALT region of the nose. By contrast, due to the potential for enhanced and rapid bioavailability, there is resurgence of interest in intranasal delivery to treat systemic disease, and particularly CNS indications, where direct nose-to-brain (N2B) delivery via targeting the olfactory region of the nose.

Content provided by our supplier

Aptar Pharma

  • FR
  • 2015
    On CPHI since
  • 5000+
Company types
Packaging supplier/manufacturer

Other Content from Aptar Pharma (39)